B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo

European Journal of Immunology

Volumn 42, Issue 12, 2012, Pages 3302-3309

  Schwab, Inessa ^a   Seeling, Michaela ^a   Biburger, Markus ^a   Aschermann, Susanne ^a   Nitschke, Lars ^a   Nimmerjahn, Falk ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Autoimmune disease; B cells; CD22; Inflammation; IVIg

Indexed keywords

ANTIINFLAMMATORY AGENT; CD22 ANTIGEN; IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; B LYMPHOCYTE; CELL ACTIVATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MICE; MICE, KNOCKOUT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SIALIC ACID BINDING IG-LIKE LECTIN 2;

EID: 84871276532     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242710     Document Type: Article

References (53)

1. Imbach, P., Barandun, S., d'Apuzzo, V., Baumgartner, C., Hirt, A., Morell, A., Rossi, E.et al., High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981. 1: 1228-1231.
2. Bayry, J., Negi, V. S.andKaveri, S. V., Intravenous immunoglobulin therapy in rheumatic diseases. Nat. Rev. Rheumatol. 2011. 7: 349-359.
3. Negi, V. S., Elluru, S., Siberil, S., Graff-Dubois, S., Mouthon, L., Kazatchkine, M. D., Lacroix-Desmazes, S. et al., Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 2007. 27: 233-245.
4. Nimmerjahn, F. and Ravetch, J. V., Anti-inflammatory actions of intravenous immunoglobulin. Ann. Rev. Immunol. 2008. 26: 513-533.
5. Seite, J. F., Shoenfeld, Y., Youinou, P. and Hillion, S., What is the contents of the magic draft IVIg? Autoimmun. Rev. 2008. 7: 435-439.
6. Anthony, R. M., Kobayashi, T., Wermeling, F. and Ravetch, J. V., Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011. 475: 110-113.
7. Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C. and Ravetch, J. V., Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008. 320: 373-376.
8. Bruhns, P., Samuelsson, A., Pollard, J. W. and Ravetch, J. V., Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003. 18: 573-581.
9. Debre, M., Bonnet, M. C., Fridman, W. H., Carosella, E., Philippe, N., Reinert, P., Vilmer, E.et al., Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 1993. 342: 945-949.
10. Kaneko, Y., Nimmerjahn, F., Madaio, M. P. and Ravetch, J. V., Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 2006. 203: 789-797.
11. Kaneko, Y., Nimmerjahn, F. and Ravetch, J. V., Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006. 313: 670-673.
12. Anthony, R. M., Wermeling, F., Karlsson, M. C. and Ravetch, J. V., Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. USA 2008. 105: 19571-19578.
13. Schwab, I., Biburger, M., Kronke, G., Schett, G. and Nimmerjahn, F., IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur. J. Immunol. 2012. 42: 826-830.
14. Scallon, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N. and Raju, T. S., Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 2007. 44: 1524-1534.
15. Crow, A. R., Song, S., Freedman, J., Helgason, C. D., Humphries, R. K., Siminovitch, K. A. and Lazarus, A. H., IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood. 2003. 102: 558-560.
16. Samuelsson, A., Towers, T. L. and Ravetch, J. V., Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001. 291: 484-486.
17. Leontyev, D., Katsman, Y. and Branch, D. R., Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fc gamma receptor for the amelioration of experimental ITP. Blood 2012. 119: 5261-5264.
18. Tackenberg, B., Jelcic, I., Baerenwaldt, A., Oertel, W. H., Sommer, N., Nimmerjahn, F. and Lunemann, J. D., Impaired inhibitory Fc gamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl. Acad. Sci. USA 2009. 106: 4788-4792.
19. Nikolova, K. A., Tchorbanov, A. I., Djoumerska-Alexieva, I. K., Nikolova, M. and Vassilev, T. L., Intravenous immunoglobulin up-regulates the expression of the inhibitory Fc gamma IIB receptor on B cells. Immunol. Cell Biol. 2009. 87: 529-533.
20. Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D. and Anderton, S. M., B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 2002. 3: 944-950.
21. Mauri, C. and Bosma, A., Immune regulatory function of B cells. Annu. Rev. Immunol. 2012. 30: 221-241.
22. Lampropoulou, V., Calderon-Gomez, E., Roch, T., Neves, P., Shen, P., Stervbo, U., Boudinot, P. et al., Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity. Immunol Rev. 2010. 233: 146-161.
23. Seite, J. F., Guerrier, T., Cornec, D., Jamin, C., Youinou, P. and Hillion, S., TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase. J. Autoimmun. 2011. 37: 190-197.
24. Jellusova, J. and Nitschke, L., Regulation of B cell functions by the sialic acid-binding receptors siglec-G and CD22. Front Immunol. 2011. 2: 96.
25. Seite, J. F., Cornec, D., Renaudineau, Y., Youinou, P., Mageed, R. A. and Hillion, S., IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 2010. 116: 1698-1704.
26. Bayry, J., Fournier, E. M., Maddur, M. S., Vani, J., Wootla, B., Siberil, S., Dimitrov, J. D. et al., Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J. Autoimmun. 2011. 36: 9-15.
27. Heidt, S., Roelen, D. L., Eijsink, C., Eikmans, M., Claas, F. H. and Mulder, A., Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production. Clin. Exp. Immunol. 2009. 158: 99-105.
28. Prasad, N. K., Papoff, G., Zeuner, A., Bonnin, E., Kazatchkine, M. D., Ruberti, G. and Kaveri, S. V., Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J. Immunol. 1998. 161: 3781-3790.
29. Baudino, L., Nimmerjahn, F., Shinohara, Y., Furukawa, J., Petry, F., Verbeek, J. S., Nishimura, S. et al., Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions. J. Immunol. 2008. 181: 4107-4112.
30. Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H., Woigk, M. et al., Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 2011. 35: 932-944.
31. Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F. and Tedder, T. F., Antibody isotype-specific engagement of Fc gamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 2006. 203: 743-753.
32. Ji, H., Ohmura, K., Mahmood, U., Lee, D. M., Hofhuis, F. M., Boackle, S. A., Takahashi, K. et al., Arthritis critically dependent on innate immune system players. Immunity 2002. 16: 157-168.
33. Akilesh, S., Petkova, S., Sproule, T. J., Shaffer, D. J., Christianson, G. J. and Roopenian, D., The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J. Clin. Invest. 2004. 113: 1328-1333.
34. Anthony, R. M. and Nimmerjahn, F., The role of differential IgG glycosylation in the interaction of antibodies with Fc gamma Rs in vivo. Curr. Opin. Organ Transplant. 2010. 16: 7-14.
35. Crow, A. R., Brinc, D. and Lazarus, A. H., New insight into the mechanism of action of IVIg: the role of dendritic cells. J. Thromb. Haemost. 2009. 7(Suppl 1): 245-248.
36. Crow, A. R. and Lazarus, A. H., The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med. Rev. 2008. 22: 103-116.
37. Kasermann, F., Boerema, D. J., Ruegsegger, M., Hofmann, A., Wymann, S., Zuercher, A. W. and Miescher, S., Analysis and functional consequences of increased fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One 2012. 7: e37243.
38. Tackenberg, B., Nimmerjahn, F. and Lunemann, J. D., Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. J. Clin. Immunol. 2010. 30 (Suppl 1): S65-69.
39. Kazatchkine, M. D. and Kaveri, S. V., Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 2001. 345: 747-755.
40. Crow, A. R., Song, S., Semple, J. W., Freedman, J.and Lazarus, A. H., A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood. 2007. 109: 155-158.
41. Guhr, T., Bloem, J., Derksen, N. I., Wuhrer, M., Koenderman, A. H., Aalberse, R. C. and Rispens, T., Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 2011. 6: e21246.
42. Stadlmann, J., Weber, A., Pabst, M., Anderle, H., Kunert, R., Ehrlich, H. J., Peter Schwarz, H. et al., A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 2009. 9: 4143-4153.
43. Bohm, S., Schwab, I., Lux, A. and Nimmerjahn, F., The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin. Immunopathol. 2012. 34: 443-453.
44. Brownlie, R. J., Lawlor, K. E., Niederer, H. A., Cutler, A. J., Xiang, Z., Clatworthy, M. R., Floto, R. A. et al., Distinct cell-specific control of autoimmunity and infection by Fc gamma RIIb. J. Exp. Med. 2008. 205: 883-895.
45. Smith, K. G. and Clatworthy, M. R., Fc gamma RIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 2010. 10: 328-343.
46. Xiang, Z., Cutler, A. J., Brownlie, R. J., Fairfax, K., Lawlor, K. E., Severinson, E., Walker, E. U. et al., Fc gamma RIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 2007. 8: 419-429.
47. Paquin Proulx, D., Aubin, E., Lemieux, R. and Bazin, R., Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin. Immunol. 2010. 135: 422-429.
48. van Kooyk, Y. and Geijtenbeek, T. B., DC-SIGN: escape mechanism for pathogens. Nat. Rev. Immunol. 2003. 3: 697-709.
49. Bolland, S. and Ravetch, J. V., Spontaneous autoimmune disease in Fc (gamma) RIIB-deficient mice results from strain-specific epistasis. Immunity 2000. 13: 277-285.
50. Bolland, S., Yim, Y. S., Tus, K., Wakeland, E. K. and Ravetch, J. V., Genetic modifiers of systemic lupus erythematosus in Fc gamma RIIB(-/-) mice. J. Exp. Med. 2002. 195: 1167-1174.
51. Boross, P., Arandhara, V. L., Martin-Ramirez, J., Santiago-Raber, M. L., Carlucci, F., Flierman, R., van der Kaa, J. et al., The inhibiting Fc receptor for IgG, Fc gamma RIIB, is a modifier of autoimmune susceptibility. J. Immunol. 2011. 187: 1304-1313.
52. Nimmerjahn, F., Bruhns, P., Horiuchi, K. and Ravetch, J. V., Fc gamma RIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005. 23: 41-51.
53. Nimmerjahn, F. and Ravetch, J. V., Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005. 310: 1510-1512.